UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Several technologies for hemoglobinopathies are being transferred to commercial partners
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
The initiative successfully demonstrates that used medical plastic packaging can be recycled and transformed back into new, contact-sensitive medical packaging
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
Subscribe To Our Newsletter & Stay Updated
